Cayman Chemical

A non-agonist PPARγ ligand (Ki = 10 nM) which blocks Cdk5-mediated phosphorylation; does not inhibit activation of PPARγ by rosiglitazone.

A small molecule inhibitor of cyclins D1-D3 expression that inhibits PI3K activity and arrests cells at the G0/G1 phase in a dose-dependent manner (5-10 μM); induces apoptosis in myeloma and leukemia cell lines (IC₅₀s = < 10 μM) and delays tumor growth in mouse models of...

Cayman's NETosis Assay Kit provides a simple and fast method for studying the process of NETosis ex vivo. Notably, Cayman's NETosis Assay Kit does not depend upon the DNA component of neutrophil extracellular traps (NETs), as DNA release can occur independently of NETosis. In this kit,...

A TLR7 agonist.

An acetylated synthetic peptide from human calpastatin that strongly inhibits both calpains I and II but not papain or trypsin.

A selective, nonpeptide CCR1 antagonist that can displace the endogenous CCR1 ligands, MIP-1α, RANTES, and MCP-3 with Ki values of 1, 2.8, and 5.5 nM, respectively; reduces chemotaxis of inflammatory cells in models of multiple sclerosis, sepsis, rheumatoid arthritis, and lupus nephritis.

A cell-permeable fluorescent probe that freely enters living cells, where it is transformed into a cell-impermeable, soluble, fluorescent compound; does not affect cell viability or proliferation and stably fluoresces for at least 72 hours, allowing for its use in cell tracking.

A compound produced from the metabolism of the organophosphorus solvent, TBP.

A linear mixed-type inhibitor of nNOS having a Ki value of 2.69 µM; normally present in small quantities in the cerebral cortex of cats with increased levels following seizure.

An endogenous nucleotide sugar that binds the P2Y14 receptor (EC₅₀ = 0.35 μM) as well as GPR17; induces oligodendrocyte differentiation at a maximal concentration of 100 μM.

An inhibitor of Chk1 that blocks phosphorylation of cdc25 with an IC₅₀ value of 15 nM; releases G2 cell cycle arrest induced by γ-irradiation or topotecan.

A potent EP4 agonist, triggering cAMP signaling with an EC₅₀ value of 0.8 nM.

An inhibitor of both α- and β-glucosidases, inhibiting lysosomal and neutral α-glucosidases with Ki values of 0.1 and 10 μM, respectively, and lysosomal and cytosolic β-glucosidases with Ki values of 7 and 40 μM, respectively; blocks N-linked glycosylation, affecting...

A bisperoxovanadium compound that selectively inhibits PTEN (IC₅₀ = 14 nM); also inhibits the vascular endothelial protein tyrosine phosphatase, PTP-β (IC₅₀ = 4.9 μM), and PTP-1βB (IC₅₀ = 25.3 μM) with reduced potency.

Antigen: human VE-cadherin amino acids 259-434 Host: rabbit Cross Reactivity: (+) human, bovine, and mouse VE-cadherin Application(s): WB, ICC, and IP

A cell-permeant glutamic acid derivative that enhances insulin release in response to glucose in isolated islets and in animal models of diabetes; also potentiates the insulinotropic potential of glyburide and GLP-1.

PGF2α 1,15-lactone is a lipid-soluble internal ester of PGF2α. Hydrolysis of the lactone readily produces free PGF2α in plasma. In rhesus monkeys, a total dose of 15 mg of PGF2α 1,15-lactone terminates early pregnancy, whereas PGF2α is ineffective.

Immunogen: Peptide from the C-terminal region of rat RSK2 Host: rabbit Species Reactivity: (+) rat RSK2 Application(s): WB RSKs 1-4 are downstream members of the ERK/MAPK cascade. Recent work suggests that RSK2 exerts a tonic regulation on G protein-coupled signaling.

A selective antagonist of the activation of VEGFR-3 by VEGF-C (IC₅₀ = 1 µM); does not inhibit ligand-induced autophosphorylation of VEGFR-2, EGFR, IGF-1R, or PDGFRβ; reduces proliferation and induces apoptosis in a variety of cancer cells in vitro and suppresses tumor growth in...

PGF2α 1,11-lactone is a lipid-soluble internal ester of PGF2α. Hydrolysis of the lactone by plasma esterases readily produces free PGF2α in rats and monkeys, but not in humans. PGF2α 1,11-lactone is active as an antifertility agent with greatly reduced vasoactivity compared...

A selective inhibitor of mutant B-RafV600E (IC₅₀ = 0.8 nM), with 4- and 6-fold reduced potency against wild type B-Raf and c-Raf (IC₅₀s = 3.2 and 5 nM, respectively); studied in clinical trials in patients with B-RafV600E metastatic melanoma and other solid tumors.

Shows selective cytotoxicity against quiescent cancer cells (IC₅₀ = 1-10 µM); induces necrosis in non-proliferating quiescent core cells in multicellular spheroids formed from HCT116 colon cancer cells; displays antitumor activity against colon cancer xenografts with minimal...

An NSAID that acts as a COX-2 inhibitor (IC₅₀s = 20 and 322 nM for COX-1 and COX-2, respectively).

A class III antiarrhythmic agent; inhibits KCNH2 with an IC₅₀ value of 1 µM; also inhibits CYP2C8 and CYP3A4 in vitro at low micromolar concentrations.